Clinical Evidence Summary - Irritable Bowel Syndrome and a Dual Strain Probiotic

Irritable bowel syndrome (IBS) is increasingly recognised as a disorder of gut-brain interaction, where gastrointestinal symptoms often coexist with stress, anxiety, fatigue and reduced quality of life. This clinical evidence summary explores the science behind a dual-strain probiotic combining Bifidobacterium longum 35624™ and Bifidobacterium longum 1714™, two clinically studied strains selected for their complementary actions on the microbiota-gut-brain axis.

Designed for healthcare professionals, the report reviews clinical trial and real-world evidence evaluating the impact of this dual-strain approach on both gastrointestinal and psychological symptoms of IBS. It also examines underlying mechanisms, patient-reported outcomes, and the rationale for targeting the gut-brain axis as part of a broader IBS management strategy.

• Clinical evidence for Bifidobacterium longum 35624™ and 1714™ in IBS, including studies assessing gastrointestinal and psychological symptom outcomes.
• Gut-brain axis-focused probiotic strategy developed to address both digestive and psychosocial aspects of irritable bowel syndrome.
• Research on IBS symptom severity, abdominal pain, bloating, stress, anxiety and quality of life following dual-strain probiotic supplementation.
• Clinical and real-world evidence insights supporting a complementary strain approach for patients with IBS and associated psychosocial symptoms.
• Mechanistic overview of microbiota-gut-brain interactions, including immune, inflammatory and stress-response pathways relevant to IBS management.